Colleagues Amanda Glassman and Bill Savedoff posted an excellent piece on the role of the World Bank, the US Agency for International Development, and other nontrade agencies in helping developing countries fend off the “Big Tobacco Bullies.” They argue that agencies like the World Bank could use their money, technical assistance, and policy dialogue to provide big visible support for developing countries to implement their anti-tobacco policies.
CGD Policy Blogs
After years of growing concern that the extensive use of antibiotics in animals was leading to the spread of drug-resistant infections, the US Food and Drug Administration (FDA) has issued a final guidance document that seeks to eliminate the use of critical antibiotics to promote growth in animals.
Value for money was at the top of our agenda this year, so I was pleased to see the topic also top the list of CGD’s most popular Global Health Policy blogs in 2013. The rest of this year’s list is a mixed bag, reflecting a number of debates that will likely stick around in 2014 (data for development, universal health coverage, and the state of global health financing, to name a few).
Over the last few months, we have been busy tracking and analyzing a number of notable developments in the global AIDS space. So in commemoration of World AIDS Day, marked annually on December 1st, here is a roundup of what we’ve been talking about, complete with links to our most recent work.
The Global Fund to Fight AIDS, TB and Malaria will host its fourth replenishment meeting this week in Washington, DC where it’s hoping to raise $15 billion to support its work for the next three years. On the eve of the replenishment, the BBC will air a 30-minute segment on its show Panorama titled “Where’s Our Aid Money Gone” that – judging by the synopsis – will likely take a more critical view of the Global Fund than much of its recent press (see here, here, and here).
Last year, PEPFAR submitted guidelines which encouraged country staff to submit a proposal to conduct an “impact evaluation” (IE) as part of their annual Country Operation Plan (COP). Subsequently, they received four submissions, of which three were funded. But they also learned that many PEPFAR staff – who are mostly program implementers, or the managers of program implementers – didn’t fully understand what they were being asked to do; what does PEPFAR mean by “impact evaluations”?
Earlier this month, Ambassador Goosby officially announced that he was stepping down from his role as Global AIDS Coordinator where he led the President’s Emergency Plan for AIDS Relief for the past four years. As my colleague Amanda blogged in anticipation of Dr. Goosby’s departure, his service will be remembered for strengthening the evidence base behind PEPFAR’s work.
It’s one thing to measure the quality of AIDS care; it’s another to understand how to improve it. Our last blog showed how the metaphor of the “treatment cascade” can be a useful way to conceptualize and measure the quality of AIDS care and that PEPFAR supported care has room for improvement on this measure (see more on the treatment cascade here). In order to achieve the health benefits that would result from reducing patient attrition over the course of the treatment cascade, PEPFAR and its partners need to learn why some facilities do better than others and what factors contributors to treatment success.